HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Overview

The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly.

Full Title of Study: “A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2006

Detailed Description

The schedule of treatment includes vinorelbine (30 mg/m2 on days 1 & 8 every 21 days) and trastuzumab (8 mg/kg on day 1 and then 6 mg/kg every 21 days). Vinorelbine is planned for maximum 9 cycles, while trastuzumab can be continued until progression. This study is a single-stage phase 2 design, and patients eligible for response evaluation are required.

Interventions

  • Drug: trastuzumab
  • Drug: vinorelbine

Clinical Trial Outcome Measures

Primary Measures

  • response rate
  • toxicity

Secondary Measures

  • time to progression
  • overall survival

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically or cytologically confirmed breast cancer – Stage IV – No prior or not more than one prior chemotherapy for metastatic disease – Overexpression of HER-2 (3+ on immunohistochemical exam) or amplified genetic expression of c-erbB2/neu (positive by Fish method) – Performance status 0-2 (ECOG) Exclusion Criteria:

  • Absence of measurable disease – Life expectancy < 3 months – Concomitant malignancy or malignancy within previous 5 years (except basal cell or spinocellular skin cancer and in situ cervical cancer if they have been adequately treated – Previous treatment with trastuzumab or vinorelbine – Neutrophils < 1500/mm3 or platelets < 100000/mm3 or haemoglobin < 8 g/dl – Creatinine > 1.5 x the value of the upper normal limit – GOT and/or GPT > 2.5 x the value of the upper normal limit and/or bilirubin > 1.5 x the value of the upper normal limit in the absence of liver metastases – GOT and/or GPT > 5 x the value of the upper normal limit and/or bilirubin > 3 x the value of the upper normal limit in the presence of liver metastases – Left ventricular ejection fraction < 50% (measured by ultrasound or MUGA angiography) – Concomitant conditions that contraindicate the use of the drugs in the protocol – Male gender – Pregnancy or lactation· – Incapacity or refusal to provide informed consent – Inability to comply with followup

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Cancer Institute, Naples
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Andrea De Matteis, M.D., Principal Investigator, NCI Naples, Division of Medical Oncology C
    • Francesco Perrone, M.D., Ph.D., Principal Investigator, NCI Naples, Clinical Trials Unit

Citations Reporting on Results

De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer. 2007 Mar 20;7:50. doi: 10.1186/1471-2407-7-50.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.